These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23663281)

  • 1. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
    Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
    BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
    Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
    Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Lenox-Smith A; Greenstreet L; Burslem K; Knight C
    Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
    Young AH; Evitt L; Brignone M; Diamand F; Atsou K; Campbell R; Cure S; Danchenko N
    J Affect Disord; 2017 Aug; 218():291-298. PubMed ID: 28478358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
    Armstrong EP; Malone DC; Erder MH
    Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH; Gordon LG
    Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pharmacogenetic screening in the management of major depressive disorder in the Spanish Healthcare System.
    Lopez-Saavedra J; Abad-Santos F
    J Affect Disord; 2024 Nov; 365():597-605. PubMed ID: 39187185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G; Danchenko N; Despiegel N; Marteau F
    Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.